# Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients

> **NCT06915389** · — · RECRUITING · sponsor: **Qinghai Red Cross Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Gastric Cancer
- Immunotherapy
- Adverse Event
- Metabonomics
- Lipidomics

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06915389
- **Lead sponsor:** Qinghai Red Cross Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-22
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06915389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06915389, "Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06915389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*